| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Vindesine sulfate (substance) |
Is a |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Pleurodesis with cancer chemotherapy substance |
Direct substance |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
1 |
| Leuprorelin (substance) |
Is a |
True |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Vinca alkaloid |
Is a |
True |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Nilutamide |
Is a |
True |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Bortezomib (substance) |
Is a |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Gefitinib (substance) |
Is a |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Flutamide (substance) |
Is a |
True |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Adverse reaction to antineoplastic antibiotics |
Causative agent (attribute) |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Adverse reaction to actinomycin D |
Causative agent (attribute) |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| complexe métallique comme agent antinéoplasique |
Is a |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Proteasome inhibitor |
Is a |
True |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Epidermal growth factor receptor inhibitor |
Is a |
True |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Angiogenesis inhibitor |
Is a |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Organic sulfone compound |
Is a |
True |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Tositumomab (substance) |
Is a |
True |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Chemotherapy administration, subcutaneous, with local anesthesia |
Direct substance |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
1 |
| Chemotherapy administration into peritoneal cavity requiring paracentesis |
Direct substance |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
2 |
| Chemotherapy administration into pleural cavity requiring thoracentesis |
Direct substance |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
4 |
| Intra-arterial infusion of antineoplastic agent |
Direct substance |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
1 |
| Imiquimod (substance) |
Is a |
True |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| 5-aminolevulinic acid (substance) |
Is a |
True |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Asparaginase (substance) |
Is a |
True |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| chimiothérapie subcutanée |
Direct substance |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
1 |
| Gallium nitrate |
Is a |
True |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Dimethyl sulfoxide |
Is a |
True |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Samarium (153-Sm) lexidronam (substance) |
Is a |
True |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Cyproterone |
Is a |
True |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| bacille de Calmette-Guérin atténué |
Is a |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Product containing aromatase inhibitor (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Product containing cytokine (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Product containing finasteride (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| nausées et vomissements provoqués par la chimiothérapie |
Causative agent (attribute) |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| chimiothérapie intraveineuse |
Direct substance |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
1 |
| Antineoplastic anthraquinone |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Finasteride 5 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Stilbestrol+lactic acid 500micrograms/5% pessary |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Diethylstilbestrol 1 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely diethylstilbestrol 5 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Megestrol acetate 40 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Megestrol acetate 160 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Cytostatic drugs |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Antineoplastic metal complex preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Product containing proteasome inhibitor (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Arsenic trioxide 1mg/mL injection 10mL ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Alkyl sulfonate antineoplastic |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Product containing arsenic (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Product containing alkylating agent (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| agent antinéoplasique |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Antineoplastic antibiotic |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Product containing megestrol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Diethylstilbestrol diphosphate preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Product containing antimetabolite (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Product containing diethylstilbestrol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Product containing megestrol acetate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Product containing synthetic antiandrogen |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| fœtus ou nouveau-né affecté par le transfert placentaire ou mammaire d'un agent chimiothérapeutique |
Causative agent (attribute) |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
1 |
| Cytotoxic given orally |
Direct substance |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
1 |
| Ibritumomab tiuxetan |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Ibritumomab tiuxetan 1.6mg/mL radiopharmaceutical infusion kit |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Stilbestrol [gynecological use] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Drugs used in malignant disease and for immunosuppression |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Other cytotoxic drugs |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Antagonists + cytotoxics |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Stilbestrol [malignancy] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Other antineoplastic agents |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Product containing abarelix (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Abarelix 100mg powder for injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely gemtuzumab ozogamicin 5 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Finasteride 1 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Megestrol acetate 40 mg/mL oral suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Product containing ibritumomab tiuxetan (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Ibritumomab tiuxetan 3.2mg injection solution 2mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Product containing dutasteride (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely dutasteride 500 microgram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Product containing gemtuzumab ozogamicin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Megestrol acetate 20 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely megestrol acetate 125 milligram/1 milliliter conventional release oral suspension (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Product containing diethylstilbestrol and lactic acid (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Toxicity due to chemotherapy |
Causative agent (attribute) |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Product containing arsenic trioxide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| alcaloïde antinéoplasique |
Is a |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Product containing rituximab (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Rituximab 10mg/mL injection concentrate 10mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Rituximab 10mg/mL infusion concentrate 50mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Secondary chemoprophylaxis |
Direct substance |
True |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
1 |
| Primary chemoprophylaxis |
Direct substance |
True |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
1 |
| Product containing acetarsol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Antineoplastic alkaloid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Administration of prophylactic antineoplastic agent |
Direct substance |
True |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
1 |
| Ibritumomab tiuxetan (substance) |
Is a |
True |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Vorinostat (substance) |
Is a |
True |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Infusion chemotherapy for malignant neoplasm |
Direct substance |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
1 |
| Instillation of antineoplastic agent into urinary bladder (procedure) |
Direct substance |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
1 |
| Temsirolimus (substance) |
Is a |
True |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Oblimersen (substance) |
Is a |
True |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Acral erythema due to cytotoxic therapy (disorder) |
Causative agent (attribute) |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Stomatitis due to cytotoxic therapy (disorder) |
Causative agent (attribute) |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Cutaneous inflammation due to cytotoxic therapy (disorder) |
Causative agent (attribute) |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Nail dystrophy due to cytotoxic therapy (disorder) |
Causative agent (attribute) |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
| Congenital malformation caused by cytotoxic agents (disorder) |
Causative agent (attribute) |
False |
Antineoplastic agent (substance) |
Inferred relationship |
Some |
|
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]